Cambrex Corporation

Global Merchant API Market to Reach $90.97 Billion by 2023, Fueled by Rising Diabetes Incidence and Growing Outsourcing Trend - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 9, 2023
Health, Pharmaceutical, Molecule, Synthetic, Incidence, Patent, Therapy, Government, Peptide, ROW, Conditional sentence, Urbanization, Generic, CDMO, Developed country, Research, R, Population growth, Artificial intelligence, Pfizer, Growth, Thermo Fisher Scientific, COVID-19, Marketing, Teva, API, Macromolecule, Machine learning, Merchant, Compound annual growth rate, Fine chemical, Biotechnology, Cambrex Corporation

The global merchant API market is on track to achieve a market value of US$90.97 billion by 2023, with a notable Compound Annual Growth Rate (CAGR) of 6.97% over the forecast period.

Key Points: 
  • The global merchant API market is on track to achieve a market value of US$90.97 billion by 2023, with a notable Compound Annual Growth Rate (CAGR) of 6.97% over the forecast period.
  • Pharmaceutical companies are increasingly outsourcing manufacturing to focus on core competencies like research and development (R&D) and marketing, contributing to the growth of the merchant API market.
  • The global merchant API market is segmented as follows:
    Molecular Type: This segment is divided into Small Molecules and Large Molecules.
  • Small molecules currently hold the largest market share due to the growing demand for small-molecule drugs and the outsourcing trend.

Cambrex Announces Sale of Drug Product Business Unit

Retrieved on: 
Thursday, November 2, 2023
Sale, CDMO, Acquisition, Growth, Approved Drug Products with Therapeutic Equivalence Evaluations, API, Cambrex Corporation, Patient, Fine chemical, Johnson & Johnson, Montréal–Mirabel International Airport

EAST RUTHERFORD, N.J., Nov. 2, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), has today completed the sale of its Drug Product Business Unit to Wilmington, Delaware based Noramco.

Key Points: 
  • EAST RUTHERFORD, N.J., Nov. 2, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), has today completed the sale of its Drug Product Business Unit to Wilmington, Delaware based Noramco.
  • Cambrex's Drug Product business provides product development, clinical and commercial manufacturing, and packaging from facilities in Mirabel, Québec, Canada and Whippany, New Jersey, USA.
  • "Looking forward, Cambrex will prioritize our drug substance and analytical testing portfolios, enabling our customers to develop and deliver therapeutic solutions for patients around the world."
  • Cambrex will continue to operate 13 global sites focused on providing drug substance development and manufacturing services across the entire drug lifecycle for customers globally.

Cambrex Announces Sale of Drug Product Business Unit

Retrieved on: 
Thursday, November 2, 2023
Sale, CDMO, Acquisition, Growth, Approved Drug Products with Therapeutic Equivalence Evaluations, API, Cambrex Corporation, Patient, Fine chemical, Johnson & Johnson, Montréal–Mirabel International Airport

EAST RUTHERFORD, N.J., Nov. 2, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), has today completed the sale of its Drug Product Business Unit to Wilmington, Delaware based Noramco.

Key Points: 
  • EAST RUTHERFORD, N.J., Nov. 2, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), has today completed the sale of its Drug Product Business Unit to Wilmington, Delaware based Noramco.
  • Cambrex's Drug Product business provides product development, clinical and commercial manufacturing, and packaging from facilities in Mirabel, Québec, Canada and Whippany, New Jersey, USA.
  • "Looking forward, Cambrex will prioritize our drug substance and analytical testing portfolios, enabling our customers to develop and deliver therapeutic solutions for patients around the world."
  • Cambrex will continue to operate 13 global sites focused on providing drug substance development and manufacturing services across the entire drug lifecycle for customers globally.

Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development

Retrieved on: 
Tuesday, October 24, 2023
Temperature, Process, CDMO, Research, Foot, API, GMP, Antirrhinum, Fine chemical, Cambrex Corporation

EAST RUTHERFORD, N.J, Oct. 24, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry has been selected as the winner of the API Development Award, presented at the CPhI Pharma Awards in Barcelona, Spain.

Key Points: 
  • EAST RUTHERFORD, N.J, Oct. 24, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry has been selected as the winner of the API Development Award, presented at the CPhI Pharma Awards in Barcelona, Spain.
  • The annual award is presented to a company that demonstrates innovation in technologies, products, processes and services for the development and manufacture of active pharmaceutical ingredients (APIs).
  • "Snapdragon is truly honored to receive this award, and we're proud of our team's ability to innovate and deliver for our client."
  • "This work highlights the value of flow chemistry to achieve processing conditions not possible in traditional batch reactors," said Dr. Matthew Beaver, Director of Process Development, Amgen.

Snapdragon Chemistry, a Cambrex Company, Recognized with CPhI Pharma Award for API Development

Retrieved on: 
Tuesday, October 24, 2023
Temperature, Process, CDMO, Research, Foot, API, GMP, Antirrhinum, Fine chemical, Cambrex Corporation

EAST RUTHERFORD, N.J, Oct. 24, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry has been selected as the winner of the API Development Award, presented at the CPhI Pharma Awards in Barcelona, Spain.

Key Points: 
  • EAST RUTHERFORD, N.J, Oct. 24, 2023 /PRNewswire/ -- Cambrex, a leading global contract development and manufacturing organization (CDMO), today announced that Snapdragon Chemistry has been selected as the winner of the API Development Award, presented at the CPhI Pharma Awards in Barcelona, Spain.
  • The annual award is presented to a company that demonstrates innovation in technologies, products, processes and services for the development and manufacture of active pharmaceutical ingredients (APIs).
  • "Snapdragon is truly honored to receive this award, and we're proud of our team's ability to innovate and deliver for our client."
  • "This work highlights the value of flow chemistry to achieve processing conditions not possible in traditional batch reactors," said Dr. Matthew Beaver, Director of Process Development, Amgen.

Global Small Molecule Innovator CDMO Market Poised for Strong 6.5% CAGR Through 2031, Fueled by Rising Outsourcing Demand in Pharmaceutical Development - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 18, 2023
Other Science, Science, Molecule, Drug development, Pharmaceutical innovations, Infection, Metabolic disorder, Lonza Group, Catalent, Confidentiality, Small molecule, Therapy, Recipharm, Johnson & Johnson Pharmaceutical Research and Development, Patheon, European Journal of Pharmaceutical Sciences, Neurology, Metabolism, CDMO, Research, Journal, Outsourcing, Pharmacy, Growth, Respiratory disease, COVID-19, Commercial, Cardiovascular disease, Cambrex Corporation, Thermo Fisher Scientific, Clinical pharmaceutical scientist, Small, Flexible, Intellectual property, IP, Compound annual growth rate, AAPS, Fine chemical, Pharmaceutical industry, Biotechnology

Increasing Demand for Outsourcing Services in Drug Development: Pharmaceutical companies are increasingly outsourcing complex and resource-intensive processes such as drug substance synthesis and drug product manufacturing to CDMOs.

Key Points: 
  • Increasing Demand for Outsourcing Services in Drug Development: Pharmaceutical companies are increasingly outsourcing complex and resource-intensive processes such as drug substance synthesis and drug product manufacturing to CDMOs.
  • Intellectual Property and Confidentiality Concerns: Intellectual property (IP) and confidentiality concerns pose a restraint on the Small Molecule Innovator CDMO market.
  • The Small Molecule Innovator CDMO market is segmented into product types, stage types, customer types, therapeutic areas, and regions.
  • Notable segments include:
    Product: Small Molecule API and Small Molecule Drug Product, with Small Molecule API exhibiting the highest CAGR during the forecast period.

Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO

Retrieved on: 
Monday, October 16, 2023
Quotient, Investment, The Home Depot, Retirement, Lytx, Drug development, Business, Geraardsbergen, Senior advisor, UPS, Wells Fargo, Growth, API, Novasep, CDMO, Synthesis, Patient, Pharmaceutical industry, Management, Cambrex Corporation, Permira

Van Nieuwenhove succeeds Mark Egerton, who retires after 18 years in the role

Key Points: 
  • Van Nieuwenhove succeeds Mark Egerton, who retires after 18 years in the role
    NOTTINGHAM, England, Oct. 16, 2023 /PRNewswire/ -- Quotient Sciences ("Quotient" or the "Company"), a leading global pharmaceutical drug development and manufacturing accelerator, is pleased to announce the appointment of Thierry Van Nieuwenhove as its new Chief Executive Officer (CEO), effective 16thOctober 2023.
  • Thierry succeeds Mark Egerton who, after 18 years of successfully leading Quotient as CEO, is retiring from executive life.
  • Thierry Van Nieuwenhove joins Quotient with an extensive track record in the pharma/CDMO services industry spanning over 23 years, and with experience in both small molecules and biologics.
  • Thierry Van Nieuwenhove said: "I am honoured to join Quotient as its new CEO and lead a team dedicated to improving the lives of patients worldwide.

Quotient Sciences Appoints Thierry Van Nieuwenhove as New CEO

Retrieved on: 
Monday, October 16, 2023
Quotient, Investment, The Home Depot, Retirement, Lytx, Drug development, Business, Geraardsbergen, Senior advisor, UPS, Wells Fargo, Growth, API, Novasep, CDMO, Synthesis, Patient, Pharmaceutical industry, Management, Cambrex Corporation, Permira

Van Nieuwenhove succeeds Mark Egerton, who retires after 18 years in the role

Key Points: 
  • Van Nieuwenhove succeeds Mark Egerton, who retires after 18 years in the role
    NOTTINGHAM, England, Oct. 16, 2023 /PRNewswire/ -- Quotient Sciences ("Quotient" or the "Company"), a leading global pharmaceutical drug development and manufacturing accelerator, is pleased to announce the appointment of Thierry Van Nieuwenhove as its new Chief Executive Officer (CEO), effective 16thOctober 2023.
  • Thierry succeeds Mark Egerton who, after 18 years of successfully leading Quotient as CEO, is retiring from executive life.
  • Thierry Van Nieuwenhove joins Quotient with an extensive track record in the pharma/CDMO services industry spanning over 23 years, and with experience in both small molecules and biologics.
  • Thierry Van Nieuwenhove said: "I am honoured to join Quotient as its new CEO and lead a team dedicated to improving the lives of patients worldwide.

Cambrex Completes $38 Million Capacity Expansion in High Point, North Carolina

Retrieved on: 
Monday, October 2, 2023
API, State, R, High Point, Fine chemical, Cambrex Corporation

EAST RUTHERFORD, N.J, Oct. 2, 2023 /PRNewswire/ -- Cambrex today announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina.

Key Points: 
  • EAST RUTHERFORD, N.J, Oct. 2, 2023 /PRNewswire/ -- Cambrex today announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina.
  • "When we began this project in 2021, our vision extended far beyond capacity," said Tom Loewald, CEO, Cambrex.
  • The combination of Snapdragon Chemistry and the expansion in High Point allows clients to utilize one vendor for flow chemistry scale-up from R&D through commercialization.
  • Cambrex continues to expand its capabilities and capacity across its North American and European network to meet the growing demand for outsourced product development and manufacturing services.

Cambrex Completes $38 Million Capacity Expansion in High Point, North Carolina

Retrieved on: 
Monday, October 2, 2023
API, State, R, High Point, Fine chemical, Cambrex Corporation

EAST RUTHERFORD, N.J, Oct. 2, 2023 /PRNewswire/ -- Cambrex today announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina.

Key Points: 
  • EAST RUTHERFORD, N.J, Oct. 2, 2023 /PRNewswire/ -- Cambrex today announced the completion of its $38 million capacity expansion at its small molecule active pharmaceutical ingredient (API) manufacturing facility in High Point, North Carolina.
  • "When we began this project in 2021, our vision extended far beyond capacity," said Tom Loewald, CEO, Cambrex.
  • The combination of Snapdragon Chemistry and the expansion in High Point allows clients to utilize one vendor for flow chemistry scale-up from R&D through commercialization.
  • Cambrex continues to expand its capabilities and capacity across its North American and European network to meet the growing demand for outsourced product development and manufacturing services.